The DOI matches its Crossref record; 73 of the 74 references it cites were found in a registry or an index.
Neurodegeneration in a Transgenic Mouse Model of Multiple System Atrophy Is Associated with Altered Expression of Oligodendroglial-Derived Neurotrophic Factors
Open accessAbstract
Multiple system atrophy (MSA) is a neurodegenerative disorder characterized by striatonigral degeneration and olivo-pontocerebellar atrophy. Neuronal degeneration is accompanied by primarily oligodendrocytic accumulation of α-synuclein (αsyn) as opposed to the neuronal inclusions more commonly found in other α-synucleinopathies such as Parkinson's disease. It is unclear how αsyn accumulation in oligodendrocytes may lead to the extensive neurodegeneration observed in MSA; we hypothesize that the altered expression of oligodendrocyte-derived neurotrophic factors by αsyn may be involved. In this context, the expression of a number neurotrophic factors reportedly expressed by oligodendrocytes [glial-derived neurotrophic factor (GDNF), brain-derived neurotrophic factor (BDNF), and insulin-like growth factor 1 (IGF-1), as well as basic fibroblast growth factor 2 (bFGF2), reportedly astrocyte derived] were examined in transgenic mouse models expressing human αsyn (hαsyn) under the control of either neuronal (PDGFβ or mThy1) or oligodendrocytic (MBP) promoters. Although protein levels of BDNF and IGF-1 were altered in all the αsyn transgenic mice regardless of promoter type, a specific decrease in GDNF protein expression was observed in the MBP-hαsyn transgenic mice. Intracerebroventricular infusion of GDNF improved behavioral deficits and ameliorated neurodegenerative pathology in the MBP-hαsyn transgenic mice. Consistent with the studies in the MBP-hαsyn transgenic mice, analysis of GDNF expression levels in human MSA samples demonstrated a decrease in the white frontal cortex and to a lesser degree in the cerebellum compared with controls. These results suggest a mechanism in which αsyn expression in oligodendrocytes impacts on the trophic support provided by these cells for neurons, perhaps contributing to neurodegeneration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The precise pathogenesis of MSA remains largely unknown, however, evidence from human postmortem cases and experimental models suggest that, in addition to GCIs, myelin degeneration, axonal damage, loss of neurotrophic support, neuronal loss, astrogliosis and microglial activation are pathological events seen in multiple regions of the central nervous system (CNS) [28, 56].”
From Novel oligodendroglial alpha synuclein viral vector models of multiple system atrophy: studies in rodents and nonhuman primates (2017) · cites this paper as [56]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Moreover, decreased neurotrophic support of oligodendroglia, as shown by reductions of glial derived neurotrophic factor expression levels in MSA tg mice and human MSA samples [56], furthers the idea that oligodendrocyte dysfunction is an early pathological event leading to secondary neurodegeneration related to retrograde axonal disease.”
From Novel oligodendroglial alpha synuclein viral vector models of multiple system atrophy: studies in rodents and nonhuman primates (2017) · cites this paper as [56]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GDNF: a Glial Cell Line-Derived Neurotrophic Factor for Midbrain Dopaminergic Neurons
Lin, L.-F. H., Doherty, D. H., Lile, J. D., Bektesh, S. L., & Collins, F. (1993) · Science · doi:10.1126/science.8493557 · Cited by 3,206
α-Synuclein is phosphorylated in synucleinopathy lesions
Fujiwara, H., Hasegawa, M., Dohmae, N., Kawashima, A., Masliah, E., Goldberg, M. S., Shen, J., Takio, K., & Iwatsubo, T. (2002) · Nature Cell Biology · doi:10.1038/ncb748 · Cited by 2,174
Self-citationDirect brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease
Gill, S. S., Patel, N. K., Hotton, G. R., O'Sullivan, K., McCarter, R., Bunnage, M., Brooks, D. J., Svendsen, C. N., & Heywood, P. (2003) · Nature Medicine · doi:10.1038/nm850 · Cited by 1,290
GDNF: a Potent Survival Factor for Motoneurons Present in Peripheral Nerve and Muscle
Henderson, C. E., PHILLIPS, H. S., Pollock, R. A., Davies, A. M., Lemeulle, C., Armanini, M. P., Simmons, L. C., Moffet, B., Vandlen, R. A., Koliatsos, V. E., et al. (1994) · Science · doi:10.1126/science.7973664 · Cited by 1,273
Brain-derived neurotrophic factor in neurodegenerative diseases
Zuccato, C., & Cattaneo, E. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.54 · Cited by 947
Tu, P., Galvin, J. E., Baba, M., Giasson, B., Tomita, T., Leight, S., Nakajo, S., Iwatsubo, T., Trojanowski, J. Q., & Lee, V. M. ‐. (1998) · Annals of Neurology · doi:10.1002/ana.410440324 · Cited by 686 · cited 1×
“…is characterized neuropathologically by glial cytoplasmic inclusions (GCIs) of -synuclein ( syn), primarily in oligodendrocytes (Arima et al., 1998; Tu et al., 1998; Wakabayashi et al., 1998a,b) unlike other -synucleinopathies, such as Parkinson’s disease (PD) and dementia with Lewy bodies, which…”
BackgroundIRANMANESH, A., LIZARRALDE, G., & VELDHUIS, J. D. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-73-5-1081 · Cited by 672
α-Synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy
Wakabayashi, K., Yoshimoto, M., Tsuji, S., & Takahashi, H. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00407-8 · Cited by 643
Impaired growth hormone secretion in the adult population: relation to age and adiposity.
Rudman, D. R., Kutner, M., Rogers, C. M., Lubin, M., Fleming, G. A., & Bain, R. P. (1981) · Journal of Clinical Investigation · doi:10.1172/jci110164 · Cited by 641
New insights into brain BDNF function in normal aging and Alzheimer disease
Tapia‐Arancibia, L., Aliaga, E., Silhol, M., & Arancibia, S. (2008) · Brain Research Reviews · doi:10.1016/j.brainresrev.2008.07.007 · Cited by 589
Cited by
Sorted by citations
α-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies
Wong, Y. C., & Krainc, D. (2017) · Nature Medicine · doi:10.1038/nm.4269 · Cited by 897
Tsunemi, T., Ashe, T. D., Morrison, B. E., Epilepsia, K. S., Au, J., Vázquez‐Roque, R. A., Lazarowski, E. R., Damian, V. A., Masliah, E., & Spada, A. R. L. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003799 · Cited by 456
Self-citationGlia: Initiators and progressors of pathology in Parkinson's disease
Halliday, G. M., & Stevens, C. H. (2011) · Movement Disorders · doi:10.1002/mds.23455 · Cited by 436
Games, D., Valera, E., Spencer, B. J., Rockenstein, E. M., Mante, M., Adame, A., Patrick, C., Ubhi, K. K., Nuber, S., Sacayon, P., et al. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.5314-13.2014 · Cited by 329
Self-citationInsulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: Targets for disease modification?
Bassil, F., Fernagut, P., Bézard, E., & Meissner, W. G. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2014.02.005 · Cited by 323
Metadata
- Authors
- Ubhi, K., Rockenstein, E., Mante, M., Inglis, C., Adame, A., Patrick, C., Whitney, K., & Masliah, E.
- Affiliations
- University of California San Diego (US)
- Corresponding author
- Masliah, Eliezer
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2010-05-05
- Volume
- 30
- Issue
- 18
- Pages
- 6236-6246
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- PMC
- PMC2896284
- OpenAlex
- W2004154235
- Cited by
- 147
- References
- 74
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 3 · 2023: 2 · 2022: 8 · 2021: 9 · 2020: 12 · 2019: 12 · 2018: 8 · 2017: 14 · 2016: 9 · 2015: 10 · 2014: 17 · 2013: 17 · 2012: 10
- FWCI
- 6.47
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Neuroscience (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (AG‐022074, AG‐18440, NS044233, AG10435)
- National Institute on Aging (P01AG010435, R37AG018440, R01AG018440, AG022074, AG 18440, P01AG022074, AG10435)
- National Institute of Neurological Disorders and Stroke (P01NS044233, NS-044233)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- multiple system atrophy, alpha-synuclein, oligodendrocytes, neurotrophic factors, glial cell line-derived neurotrophic factor, brain-derived neurotrophic factor, insulin-like growth factor I, basic fibroblast growth factor, neurodegeneration, striatonigral degeneration, transgenic mouse model, intracerebroventricular infusion, white matter
- MeSH terms
- Aged, Animals, Behavior, Animal, Brain, Disease Models, Animal, Female, Humans, Injections, Intraventricular, Male, Mice, Transgenic, Nerve Degeneration, Nerve Fibers, Myelinated, Nerve Growth Factors, Neurons, Oligodendroglia, Promoter Regions, Genetic, Mice, Knockout, Multiple System Atrophy, Glial Cell Line-Derived Neurotrophic Factor, Mice, alpha-Synuclein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
